Furthermore, tumour xenograft with DOT1L-overexpressing T47D cellsor Tet-inducible DOT1L shRNA-infected MDA-MB-231 cells in non-obesediabetic/severe combined immunodeficient (NOD/SCID) mice showed that DOT1Lexpression is required for tumour-initiating ability in vivo (Table 1). This evidence concerns the gene DOT1L and neoplasm.